摘要
目的比较利培酮口服液与奥氮平治疗老年痴呆精神行为症状(BPSD)的疗效和安全性。方法将120例BPSD患者随机分为研究组和对照组各60例。研究组患者给予利培酮口服液治疗,对照组患者给予奥氮平治疗,疗程为8周。2组患者均采用痴呆病理行为评定量表(BEHAVE-AD)评定疗效,Cohan Mansfield激越行为量表(CMAI)评定激越行为的改善程度,副反应量表(TESS)评定药物不良反应,自编依从性量表观察患者服药依从性,并进行组间比较。结果在治疗第4周,2组BEHAVE-AD评分和CMAI评分较治疗前下降,但差异无统计学意义(P>0.05)。在治疗第8周,2组BEHAVE-AD评分和CMAI评分较治疗前明显下降,差异有统计学意义(P<0.01)。治疗前、治疗第4、8周2组BEHAVE-AD评分和CMAI评分比较差异无统计学意义(P>0.05)。研究组患者体质量增加、嗜睡的发生率均低于对照组,差异有统计学意义(P<0.05)。治疗第1周2组依从性无明显差异(P>0.05),从治疗第4、8周研究组依从性明显优于对照组,差异有统计学意义(P<0.05)。结论利培酮口服液应用于临床治疗老年痴呆伴发BPSD效果显著、相对安全,患者具有更好依从性。
Objective To discuss the clinical value and safety of risperidone oral solution and olanzapine in treatment of elderly dementia behavioral and psychological symptoms( BPSD). Methods 120 patients with BPSD were randomly divided into research group and control group,each of 60 cases. Research group were treated with risperidone oral solution,control group were treated with olanzapine,the treatment course was 8 weeks. Used BEHAVE-AD to evaluate the efficacy,evaluated the agitated behavior improvement by CMAI,assessed the adverse drug reactions by TESS assessment,observed the medication compliance by self compliance scale. Results 4 weeks after treatment,the BEHAVE-AD score and CMAI scores of two groups than before treatment decreased,but the difference was not statistically significant( P > 0. 05),8 weeks after treatment,the BEHAVE-AD score and CMAI scores of two groups decreased significantly,compared with before treatment difference was statistically significant( P < 0. 01). Before treatment,4 weeks,8 weeks after treatment,the difference of BEHAVE-AD scores and CMAI scores of two groups was not statistically significant( P > 0. 05). The incidence rate of weight gain,lethargy in research group were lower than control group,the difference was statistically significant( P < 0. 05). 1 week after treatment,the compliance of two groups showed no significant difference( P > 0. 05),4 weeks,8 weeks after treatment the compliance of research group was better than control group,the difference was statistically significant( P < 0. 05). Conclusion Risperidone oral solution is applied to the clinical treatment of elderly dementia with BPSD effective and relatively safe,patients with better compliance.
出处
《临床合理用药杂志》
2016年第22期13-15,共3页
Chinese Journal of Clinical Rational Drug Use
基金
青岛市卫生局医药科研计划(No:2014-WSZD150)
关键词
利培酮口服液
奥氮平
老年痴呆
精神行为症状
Olanzapine
Risperidone oral solution
Elderly dementia
Behavioral and psychological symptoms
